IN RE: SUBOXONE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE) ANTITRUST LITIGATION
Case Number:
2:13-md-02445
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
-
June 20, 2016
Suboxone Buyers Slam Comparison To Sanofi's Antitrust Win
Drug buyers bringing antitrust claims over Indivior's opiate addiction treatment Suboxone told a Pennsylvania federal judge Friday that the generic substitution system set up by federal and state law sets the Suboxone case apart from Sanofi Aventis' recent Third Circuit victory, which Indivior has cited in its own litigation.
-
May 02, 2016
Amneal Fights To Maintain Claims In Suboxone MDL
Amneal fought Friday to keep claims in multidistrict litigation accusing Indivior of embarking on a product-hopping scheme to stave off generic competition to the opiate addiction treatment Suboxone, telling a Pennsylvania federal judge it has outlined the alleged plot in great detail.
-
March 29, 2016
Indivior Keeps Fighting For Resale Docs In Antitrust Case
Indivior told a Pennsylvania federal judge Monday that it was wrongly denied information about resales of Suboxone, arguing that it needs the discovery to defend itself against allegations that it stifled generic competition for the opiate addiction treatment by pushing the market to a new drug formulation.
-
March 24, 2016
Indivior Says FDA Petition Didn't Delay Generic Suboxone
Indivior PLC told a Pennsylvania federal judge on Wednesday that its U.S. Food and Drug Administration petition did not delay the approval of generic versions of the opiate addiction treatment Suboxone, contrary to what drug buyers have claimed in litigation over an alleged "product-hopping" scheme to stifle generic competition.
-
February 09, 2016
Bid For Info On Suboxone Resales Is Premature, Judge Says
A Pennsylvania federal judge Monday ruled that direct purchasers of Suboxone who accuse manufacturer Indivior of engaging in a product-hopping scheme to stifle generic competition of the opiate addiction treatment need not turn over information about resales of the drug until a decision on the issue is reached.
-
January 29, 2016
Indivior Fights For Sales Docs In Product-Hopping Case
Reckitt Benckiser spinoff Indivior has again urged a Pennsylvania federal judge to force drug wholesalers and others who claim the companies used a so-called product-hopping scheme to stifle generic competition to Suboxone to turn over information about downstream sales of the opiate addiction treatment.
-
April 15, 2015
Judge Allows Most Claims In Suboxone MDL To Move Forward
A Pennsylvania federal judge on Tuesday mostly kept intact his decision to allow Suboxone buyers to pursue claims in multidistrict litigation that Reckitt Benckiser Pharmaceuticals Inc. violated antitrust law by using a "product-hopping" scheme to delay generic competition, but tossed certain claims against its parent company.
-
January 20, 2015
Suboxone Buyers Urge Court Against Reckitt's Recon Bid
A class of direct purchasers of Suboxone on Friday told a Pennsylvania federal court that Reckitt Benckiser Inc. can't prove a decision to allow the class to pursue its antitrust claims against the drugmaker represents an error of law, urging the court to ignore the drugmaker's reconsideration bid.
-
December 19, 2014
Reckitt Asks Judge To Again Consider Axing Suboxone Suit
Reckitt Benckiser Inc. has urged a Pennsylvania federal judge to reconsider his decision to allow Suboxone buyers to pursue claims that the drugmaker violated antitrust law by using a "product-hopping" scheme to delay generic competition for the opiate addiction treatment.
-
December 04, 2014
Reckitt Can't Escape Antitrust Case Over 'Product-Hopping'
A Pennsylvania federal judge on Wednesday trimmed a multidistrict class action against Reckitt Benckiser Inc. but said direct purchasers of the drug sufficiently backed their claim that the drugmaker used an anti-competitive "product-hopping" scheme to keep generic rivals to its opiate addiction treatment Suboxone off the market.